Articles

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

Department of Hematology, Karolinska University Hospital, Stockholm, Sweden;Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden;Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
Department of Hematology, South Älvsborg Hospital, Borås, Sweden
Department of Hematology and Vascular Disorders, Skåne University Hospital, Lund, Sweden
Department of Hematology, Karolinska University Hospital, Stockholm, Sweden;Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
Department of Hematology, Sunderby Hospital, Sunderbyn Luleå, Sweden
Department of Hematology, Karolinska University Hospital, Stockholm, Sweden;Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
Department of Hematology, Uppsala University Hospital, Uppsala, Sweden
Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
Department of Hematology, Linköping University Hospital, Linköping, Sweden
Department of Hematology, Karolinska University Hospital, Stockholm, Sweden;Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
Department of Hematology, Karolinska University Hospital, Stockholm, Sweden;Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
Vol. 101 No. 12 (2016): December, 2016 https://doi.org/10.3324/haematol.2016.144576